SiVEC Biotechnologies is an R&D company committed to developing global solutions for rapid disease protection. The company is currently focused on developing a patent-pending antiviral technology, SiVEC-AIV™, to be rapidly applied on-farm as a spray to treat and prevent all types of avian influenza viruses in poultry. This novel technology has the potential to revolutionize the way avian influenza is addressed worldwide. SiVEC-AIV™ is built on a platform technology that can be adapted for the treatment and prevention of a wide range of diseases in animals as well as humans. SiVEC Biotechnologies was recently awarded a Phase I Small Business Innovative Research (SBIR) grant by the National Institutes of Health (NIH) to support research activities focused on expanding the application of SiVEC’s nucleic acid delivery platform, including the application as an antiviral against human influenza virus.


Avian flu is a recurring global threat and which has resulted in over $40 billion USD in economic loss in the past decade. The status quo for preventing avian flu is to administer vaccine to individual birds, which is both costly and time consuming. SiVEC-AIV™ is designed to overcome nearly every limitation of current vaccines. Increasing avian flu outbreak occurrence and increasing global poultry production support a strong product opportunity and an expanding market for SiVEC-AIV™.


SiVEC-AIV™ is a novel biologic antiviral technology. It is rapidly applied to poultry flocks as a spray using industry-standard equipment, making it a sustainable and scalable solution. SiVEC-AIV™ targets the respiratory tissues and destroys all types of avian flu viruses. In pre-clinical studies, SiVEC-AIV™ has safely provided clinically relevant protection against avian flu in chickens, thereby positioning the product to protect against economic loss in the poultry industry.

For more information about SiVEC Biotechnologies and ongoing R&D activities visit

SiVEC Biotechnologies